News | Pacemakers | May 24, 2018

Permanent Pacing Effective for Older Patients With Syncope and Bifascicular Block

Study finds significant advantages with permanent pacing versus an implantable cardiac monitor for particular patient group

Permanent Pacing Effective for Older Patients With Syncope and Bifascicular Block

May 24, 2018 — Syncope with bifascicular block may be caused by intermittent complete heart block, but competing diagnoses may coexist. A new study tested whether a strategy of empiric permanent pacing (PM) reduces major adverse events more effectively than acting on the results of an implantable cardiac monitor (ICM). Results of the study were presented at Heart Rhythm 2018, the 39th annual scientific sessions of the Heart Rhythm Society (HRS), May 9-12 in Boston.

In a multinational, randomized, pragmatic trial, 56 subjects under 50 years old with bifascicular block, preserved left ventricular function, and less than or equal to one syncope in the preceding year, received PM and 59 received an ICM. The primary outcome measure was a composite of Major Adverse Study-Related Events (MASRE), comprised of death, syncope, symptomatic bradycardia, asymptomatic actionable bradycardia and device complications.

The PM and ICM groups were similar in age, sex, lifetime syncopes, syncope in prior year, duration of symptoms, no prodrome and baseline systolic BP. Forty patients had left bundle branch block and 75 had right bundle branch block and a left hemiblock. Patients were followed for a median 30 months, and 21 exited the study — eight patients died, six withdrew consent after 2 years, four withdrew due to cancer and three due to dementia.

PM effectively prevented the primary outcome with end study MASRE-free survivals in PM (63 percent) and ICM (22 percent) group (p<0.001). The proportions of patients with syncope were similar in PM and ICM groups (27 vs 31 percent, p=0.50, Wilcoxon). Fully 35 out of 59 ICM patients (59 percent) crossed over to PM. There were five pacemaker complications requiring reintervention.

The researchers concluded that permanent pacing compared to ICM is a preferred strategy in elderly patients with few but recent syncopal spells and bifascicular block. This is driven by the high proportion of mildly symptomatic bradycardias detected on ICMs leading to pacemaker insertion.

For more information: www.hrssessions.org

Read more about HRS 2018 late-breaking studies


Related Content

News | Cardiovascular Clinical Studies

September 8, 2022 — A clinical trial led by investigators from Brigham and Women’s Hospital has found that the long-term ...

Home September 08, 2022
Home
News | Cardiovascular Clinical Studies

August 17, 2022 — A study carried out by scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) ...

Home August 17, 2022
Home
News | Cardiovascular Clinical Studies

August 12, 2022 — Older adults with atrial cardiopathy (a major, often undetected cardiac cause of stroke) may be at ...

Home August 12, 2022
Home
News | Cardiovascular Clinical Studies

August 8, 2022 — Two years ago, University of Alabama at Birmingham researchers and colleagues reported that reductive ...

Home August 08, 2022
Home
News | Cardiovascular Clinical Studies

July 22, 2022 — BioSig Technologies, Inc. a medical technology company advancing electrophysiology workflow by ...

Home July 22, 2022
Home
News | Cardiovascular Clinical Studies

July 18, 2022 — scPharmaceuticals Inc., a pharmaceutical company focused on developing and commercializing products that ...

Home July 19, 2022
Home
News | Cardiovascular Clinical Studies

July 15, 2022 — Imagine, if scientists had a map of the heart, so granular in its accuracy that it even profiled details ...

Home July 15, 2022
Home
News | Cardiovascular Clinical Studies

July 11, 2022 — Smoking traditional or non-combustible cigarettes while wearing a surgical mask results in a two-fold ...

Home July 12, 2022
Home
News | Cardiovascular Clinical Studies

June 24, 2022 — Henry Ford Health was part of a multi-institutional heart failure study that was launched and executed ...

Home June 24, 2022
Home
News | Cardiovascular Clinical Studies

June 21, 2022 — Renibus Therapeutics (“Renibus”), a clinical-stage biotech company focusing on the prevention and ...

Home June 21, 2022
Home
Subscribe Now